These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 24627546)
1. Bad liver and a broken heart. Coates TD Blood; 2014 Mar; 123(10):1434-6. PubMed ID: 24627546 [TBL] [Abstract][Full Text] [Related]
2. A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA). Pennell DJ; Porter JB; Piga A; Lai Y; El-Beshlawy A; Belhoul KM; Elalfy M; Yesilipek A; Kilinç Y; Lawniczek T; Habr D; Weisskopf M; Zhang Y; Aydinok Y; Blood; 2014 Mar; 123(10):1447-54. PubMed ID: 24385534 [TBL] [Abstract][Full Text] [Related]
3. Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. Pennell DJ; Porter JB; Piga A; Lai YR; El-Beshlawy A; Elalfy M; Yesilipek A; Kilinç Y; Habr D; Musallam KM; Shen J; Aydinok Y; Am J Hematol; 2015 Feb; 90(2):91-6. PubMed ID: 25345697 [TBL] [Abstract][Full Text] [Related]
4. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients. Cassinerio E; Orofino N; Roghi A; Duca L; Poggiali E; Fraquelli M; Zanaboni L; Cappellini MD Blood Cells Mol Dis; 2014 Sep; 53(3):164-7. PubMed ID: 24846580 [TBL] [Abstract][Full Text] [Related]
5. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia. Saliba AN; El Rassi F; Taher AT Expert Rev Hematol; 2016; 9(2):151-68. PubMed ID: 26613264 [TBL] [Abstract][Full Text] [Related]
6. Using of deferasirox and deferoxamine in refractory iron overload thalassemia. Takpradit C; Viprakasit V; Narkbunnam N; Vathana N; Phuakpet K; Pongtanakul B; Sanpakit K; Buaboonnam J Pediatr Int; 2021 Apr; 63(4):404-409. PubMed ID: 32856363 [TBL] [Abstract][Full Text] [Related]
7. Cost-utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent β-thalassemia patients. Keshtkaran A; Javanbakht M; Salavati S; Mashayekhi A; Karimi M; Nuri B Transfusion; 2013 Aug; 53(8):1722-9. PubMed ID: 23241074 [TBL] [Abstract][Full Text] [Related]
8. Combined chelation therapy with deferasirox and deferoxamine in thalassemia. Lal A; Porter J; Sweeters N; Ng V; Evans P; Neumayr L; Kurio G; Harmatz P; Vichinsky E Blood Cells Mol Dis; 2013 Feb; 50(2):99-104. PubMed ID: 23151373 [TBL] [Abstract][Full Text] [Related]
9. Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β-thalassemia major and severe iron burden. Voskaridou E; Komninaka V; Karavas A; Terpos E; Akianidis V; Christoulas D Transfusion; 2014 Mar; 54(3):646-9. PubMed ID: 23834310 [TBL] [Abstract][Full Text] [Related]
10. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. Cappellini MD; Bejaoui M; Agaoglu L; Porter J; Coates T; Jeng M; Lai ME; Mangiagli A; Strauss G; Girot R; Watman N; Ferster A; Loggetto S; Abish S; Cario H; Zoumbos N; Vichinsky E; Opitz H; Ressayre-Djaffer C; Abetz L; Rofail D; Baladi JF Clin Ther; 2007 May; 29(5):909-917. PubMed ID: 17697909 [TBL] [Abstract][Full Text] [Related]
11. Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload. Wu D; Wen X; Liu W; Hu H; Ye B; Zhou Y Drug Des Devel Ther; 2018; 12():1081-1091. PubMed ID: 29760547 [TBL] [Abstract][Full Text] [Related]
12. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study. Totadri S; Bansal D; Bhatia P; Attri SV; Trehan A; Marwaha RK Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of Deferasirox (Exjade®) in Modulation of Iron Overload in Patients with β-Thalassemia Intermedia. Karimi M; Arandi N; Haghpanah S; Ansari S; Azarkeyvan A; Bordbar M; Safaei S Hemoglobin; 2015; 39(5):327-9. PubMed ID: 26114738 [TBL] [Abstract][Full Text] [Related]
14. Current status of iron overload and chelation with deferasirox. Choudhry VP; Naithani R Indian J Pediatr; 2007 Aug; 74(8):759-64. PubMed ID: 17785900 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. Kontoghiorghe CN; Kontoghiorghes GJ Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541 [TBL] [Abstract][Full Text] [Related]
16. A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan. Ho WL; Chung KP; Yang SS; Lu MY; Jou ST; Chang HH; Yang YL; Lin DT; Lin KH J Formos Med Assoc; 2013 Apr; 112(4):221-9. PubMed ID: 23537869 [TBL] [Abstract][Full Text] [Related]
17. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Piga A; Galanello R; Forni GL; Cappellini MD; Origa R; Zappu A; Donato G; Bordone E; Lavagetto A; Zanaboni L; Sechaud R; Hewson N; Ford JM; Opitz H; Alberti D Haematologica; 2006 Jul; 91(7):873-80. PubMed ID: 16818273 [TBL] [Abstract][Full Text] [Related]
18. Deferasirox versus deferoxamine in managing iron overload in patients with Sickle Cell Anaemia: a systematic review and meta-analysis. Qadah T J Int Med Res; 2022 Dec; 50(12):3000605221143290. PubMed ID: 36562113 [TBL] [Abstract][Full Text] [Related]
19. [Curative effects and safety of deferasirox in treatment of iron overload in children with β-thalassemia major]. Gao HY; Li Q; Chen JJ; Chen GF; Li CG Zhongguo Dang Dai Er Ke Za Zhi; 2011 Jul; 13(7):531-4. PubMed ID: 21752315 [TBL] [Abstract][Full Text] [Related]
20. Deferasirox for managing iron overload in people with thalassaemia. Meerpohl JJ; Antes G; Rücker G; Fleeman N; Motschall E; Niemeyer CM; Bassler D Cochrane Database Syst Rev; 2012 Feb; (2):CD007476. PubMed ID: 22336831 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]